Curis trades higher as analysts reiterate their outlooks after the stock loses more than a third of its market value on disappointing trial results.

Curis said it would take a lower dose of its leukemia treatment into Phase 2 studies after higher doses showed toxicities.

Results showed the treatment 'provides potent and durable anti-cancer activity' for certain lymphoma patients, Curis said.

Spectrum Pharmaceuticals, BioCryst Pharmaceuticals and Curis were among the biotech stock movers in premarket trading on Thursday.

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Elon Musk will soon allow Dogecoin to purchase SpaceX merchandise.

The theme park company has opened Guardians of the Galaxy: Cosmic Rewind and not everyone is happy despite the ride getting wonderful reviews.

Aurora is slashing its production capacity as it builds a runway toward positive Ebitda a year from now.

Costco took in $984 million in new membership fee in its fiscal third quarter, helping the bulk retailer top Street forecasts for topline revenues.